Abstract 113P
Background
Tumor tissue preservation methods affect proteome profiles differently. To date, no studies have reported a deep proteome comparison of four tissue preservation methods and their corresponding proteome profiles. This study sought to assess the effect of different preservation methods on quantitative proteomics of human breast adjacent normal (NC) and tumor tissues (TC) preserved in Allprotect, snap-frozen by LN2, RNAlater, and formalin solution embedded in paraffin (FFPE).
Methods
Around 7 patients’ TC and NC were preserved in four different storage conditions, which include Allprotect, LN2, RNAlater, and FFPE. A comprehensive deep proteomics analysis using mass spectrometry has been performed to evaluate the effect of storage conditions on the preservation of proteins. Protein yield and coverage were compared in four storage conditions to determine the optimum storage conditions for tissue samples to perform proteomics analysis. Unique proteins obtained from each condition were further analyzed to examine the effect of storage conditions on subcellular location. Differential analysis was performed on all individual conditions to compare the unique statistically differentially expressed proteins.
Results
TC tissues showed the highest protein yield compared to NC because the fat portion was higher in NC. The FFPE condition, followed by RNAlater, was determined to have the maximum protein coverage. Unique proteins could be detected from FFPE samples, providing a hint of the modifications induced during the paraffinization. However, the differential analysis showed more unique proteins in the Allprotect storage conditions, followed by RNAlater. The proteins CNDP2 and PLIN4 showed dysregulation in the TC sample despite the different storage conditions and may be used as therapeutic markers for breast cancer. Biological pathway analysis showed spliceosome and PPAR signaling pathways were enriched in TC compared to NC tissue.
Conclusions
This study evaluated the effects of different tissue preservation methods on proteomics analysis.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
IIT Bombay.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
169P - A real-world molecular pre-screening program in advanced breast cancer (ABC) at Institut Català d'Oncologia l'Hospitalet: Clinical practice study to assess treatment-decision choice based on molecular results
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - KRAS status in patients with pancreatic ductal adenocarcinoma: A single-center study from 2020 to 2023
Presenter: Manukyan Mariam
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Benefit of next-generation sequencing for lung cancer patients in a limited-resource area
Presenter: Kijjakom Thanasombunsukh
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - Survival prediction using CT based radiomic features in patients of pancreatic cancer treated by chemotherapy followed by SBRT: A pilot study
Presenter: Divya Khosla
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - Overcoming monocyte imbalance and T cell exhaustion in obesity-associated colorectal cancer liver metastasis
Presenter: Alyssa Cristea
Session: Cocktail & Poster Display session
Resources:
Abstract
174TiP - A pivotal clinical trial of a functional ex vivo organ culture assay for cancer precision medicine
Presenter: Sandra Hanks
Session: Cocktail & Poster Display session
Resources:
Abstract
177TiP - Myeloid-derived suppressor cells in the peripheral blood of patients with colorectal cancer: A trial in progress
Presenter: Hans Raskov
Session: Cocktail & Poster Display session
Resources:
Abstract